Evidence map›Paper›PMID 25699148›Full record

ArticleACS medicinal chemistry letters2015

Azepinone-Containing Tetrapeptide Analogues of Melanotropin Lead to Selective hMC4R Agonists and hMC5R Antagonist.

Olivier Van der Poorten, Krisztina Fehér, Koen Buysse, Debby Feytens, Ioanna Zoi, Steven D Schwartz, José C Martins, Dirk Tourwé, Minying Cai, Victor J Hruby and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Demonstration of a Common DPheJournal of medicinal chemistry · 2022
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olivier Van der PoortenResearch Group of Organic Chemistry, Vrije Universiteit Brussel , Pleinlaan 2, B-1050 Brussels, Belgium.
Krisztina FehérDepartment of Organic Chemistry, University of Ghent , Krijgslaan 281 S4, 9000 Ghent, Belgium.
Koen BuysseResearch Group of Organic Chemistry, Vrije Universiteit Brussel , Pleinlaan 2, B-1050 Brussels, Belgium.
Debby FeytensResearch Group of Organic Chemistry, Vrije Universiteit Brussel , Pleinlaan 2, B-1050 Brussels, Belgium.
Ioanna ZoiDepartment of Chemistry and Biochemistry, University of Arizona , Tucson, Arizona 85721, United States.
Steven D SchwartzDepartment of Chemistry and Biochemistry, University of Arizona , Tucson, Arizona 85721, United States.
José C MartinsDepartment of Organic Chemistry, University of Ghent , Krijgslaan 281 S4, 9000 Ghent, Belgium.
Dirk TourwéResearch Group of Organic Chemistry, Vrije Universiteit Brussel , Pleinlaan 2, B-1050 Brussels, Belgium.
Minying CaiDepartment of Chemistry and Biochemistry, University of Arizona , Tucson, Arizona 85721, United States.
Victor J HrubyDepartment of Chemistry and Biochemistry, University of Arizona , Tucson, Arizona 85721, United States.
Steven BalletResearch Group of Organic Chemistry, Vrije Universiteit Brussel , Pleinlaan 2, B-1050 Brussels, Belgium.

Funding

Supplement for "Designing Novel Melanotropins for New Applications for the Melanocortin System"R01GM108040 · NIGMS · UNIVERSITY OF ARIZONA · PI CAI, MINYING, HRUBY, VICTOR J · 2014 to 2017
$1.2M
NIGMS NIH HHS R01 GM108040
6 · The paper itself

Abstract

To address the need for highly potent, metabolically stable, and selective agonists, antagonists, and inverse agonists at the melanocortin receptor subtypes, conformationally constrained indolo- and benzazepinone residues were inserted into the α-MSH pharmacophore, His(6)-Phe(7)-Arg(8)-Trp(9)-domain. Replacement of His(6) by an aminoindoloazepinone (Aia) or aminobenzazepinone (Aba) moiety led to hMC4R and hMC5R selective agonist and antagonist ligands, respectively (tetrapeptides 1 to 3 and 4, respectively). In peptides 1 to 3 and depending on the para-substituent of the d-Phe residue in position 2, the activity goes from allosteric partial agonism (1, R = H) to allosteric full agonism (2, R = F) and finally allosteric partial agonism (3, R = Br).

Indexed as

allosteric hMC4R ligandsconstrained aminoazepinonesfluorine peptidomimeticshMC4R and hMC5R molecular modeling and ligand dockingMelanocortin ligands

Identifiers

PMID25699148
PMCPMC4329577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.